Navigation Links
TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs
Date:10/17/2007

TEL-AVIV, Israel, October 17 /PRNewswire-FirstCall/ -- TopSpin Medical (TASE: TOPMD), the developer of a unique technology for high-resolution MRI using an IntraVascular MRI (IVMRI) catheter for the coronary arteries, announced today the appointment of Cindy Setum, Ph.D., as Vice President, Clinical Affairs.

Dr. Setum has over 15 years of experience in cardiovascular research in the medical device industry. She has a Ph.D. from the University of Minnesota, holds several medical device patents and has published extensively in the areas of cardiologic, peripheral and neurovascular applications for interventional medical devices. Dr. Setum was previously Vice President of Clinical and Medical Affairs at Possis Medical, Inc., where for 12 years she supervised preclinical and clinical research in catheter-based thrombectomy (removal of intravascular blood clots).

Yaron Tal, TopSpin's CEO, commented: "The addition of Dr. Setum to our management team as Vice President of Clinical Affairs is a significant step in building our global presence in the Cardiology market. Dr. Setum's track record of accomplishments and strong medical device background make her well suited for this position. She has the leadership skills and expertise to move our clinical research program forward."

About TopSpin

TopSpin Medical developed an innovative and unique technology for high-resolution MRI using an IntraVascular MRI (IVMRI) catheter for the coronary arteries, without the need for an expensive and bulky external MRI setup. The catheter contains those components, which are usually found in a conventional MRI scanner, only that they are miniaturized to less than 2 millimeters in size. In 2006 TopSpin Medical began to develop its technology for imaging prostate cancer by an integrated endo-rectal MRI and ultrasound probe.

STATEMENTS IN THIS PRESS RELEASE WHICH ARE NOT HISTORICAL DATA ARE FORWARD-LOOKING STATEMENTS WHICH INVOLVE KNOWN AND UNKNOWN RISKS, UNCE
'/>"/>

SOURCE TopSpin Medical Israel Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... /PRNewswire-Asia/ -- The world is going through,e...ertainty is part of many,businesses and industries...elatively immune to the economic downturn, because...g the midst of the difficult times this year, the ...ated an R&D center in Shanghai, the largest of...
(Date:12/2/2009)... According to the National Institut... diagnosed with diabetes already have some stage o...age to the retina caused by leaky blood vessels, i...es and is one of the most feared diabetic complica...who,ve had diabetes for 10 years or more will expe...
(Date:12/1/2009)...ec. 1 PDL BioPharma, Inc...uidance for the fourth quarter ended December 31, ...h $69 million for the fourth quarter of 2008. Incl...of two installment payments of $12.5 million from ...ults was a one-time $1.8 million payment from Gene...
(Date:12/1/2009)... Reportlinker.com announces that a ...alogue: ,, Industrial Enzymes - A Global Marke...431/Industrial-Enzymes---A-Global-Market-Report.ht...y with few strong players and a host of small supp...petition and commoditization characterize the indu...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10
...O, SOUTH SAN FRANCISCO, Calif., May 28 Exelixis,...alyst briefing in,conjunction with the 44th Annual...ogy (ASCO) from 6:00 p.m. to 8:00 p.m. CT on Monda...ngos, PhD, President and Chief Executive Officer ...h and Development -- Gisela M. Schwab, MD, Execut...
...website initially focusing on proteins and their r...technology underlying the site has been developed ...escribed in BioMed Centrals open access journal Ge...ommunity annotation on a huge scale. , The artic...l Center in Rotterdam, and the Leiden University M...
...tion, carbon nanotubes which are about 100,000 ti...unique and very useful properties have become the...anosized electronic and mechanical devices. But it...ell as their tendency to clump together, that make...es. , Dr. Ernesto Joselevich, together with Ph.D....
Other Biology Technology:REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO 2REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO 3REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO 4Large-scale community protein annotation -- WikiProteins 2Weizmann Institute scientists create new nanotube structures 2
(Date:12/3/2009)...e measured CO2 levels for the past three years in ... inhabited rural area near Valladolid. The results... Peninsula, show that the levels rose "significant...physicists and meteorologists have been trying to ...w these have evolved in the troposphere over vario...
(Date:12/3/2009)... Antarctic snowmelt that occurred during the 2008-...ong positive phases for two main climate drivers, ...hern Hemisphere Annular Mode), according to Dr. Ma...heric Sciences at The City College of New York. ... faculty at the CUNY Graduate Center, added that A...
(Date:12/2/2009)... results strengthen the evidence that people who s... increased risk for developing colorectal cancer, ..."This provides one more reason not to smoke, or to...hael J. Thun, M.D., M.S., vice president emeritus,...rican Cancer Society. "Colorectal cancer should be...
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2CCNY professor foresees rising Antarctic snowmelt 2Cigarette smoking increases colorectal cancer risk 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 1Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 3Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 4Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 5Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 6Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 7Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 8Vasogen and IntelliPharmaCeutics to Combine to Create Publicly traded Specialty Pharmaceutical Company 13587 9Professor Nancy Ip Joins aTyr Pharmas Scientific Advisory Board 13585 1Professor Nancy Ip Joins aTyr Pharmas Scientific Advisory Board 13585 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 13583 1BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 13583 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 13583 3
..., ISRAEL, April 28, 2009 ZenithSolar, an Israeli ...near Tel Aviv on April 26, based on concentrated p... Faiman of Ben-Gurion University of the Negev (BG...rman of the Department of Solar Energy and Environ... for Desert Research, believes the new system will...
...s will gather soon for the 61st Annual Meeting of ...ty of America, being held 11-13 May 2009 in Orem, ... meeting in their new library building on the UVU ... The technical program, presented by academic and ...e students, will highlight cutting-edge scientific...
...ll. Researchers at the University of Illinois hav...the targeted delivery of one or more molecules int... addition to ferrying tiny amounts of cargo, the n...robe and as an optical biosensor., "Nanoneedle-ba...iological processes and biophysical properties at ...
Other Biology News:Ben-Gurion University research and technology used in new solar energy farm 2Geoscientists meet to discuss Rocky Mountain geology 2Nanoneedle is small in size, but huge in applications 2
Mouse Anti-SF3B2 Polyclonal Antibody, Unconjugated from Abnova Corporation
Mouse Anti-Human FBXO11 Monoclonal Antibody, Unconjugated, Clone 4C12 from Abnova Corporation
Mouse Anti-Human LASS3 Polyclonal Antibody, Unconjugated from Abnova Corporation
Rabbit Anti-Nonmuscle Myosin II Heavy Chain B (MHC-B) Polyclonal Antibody, Unconjugated from Covance Research Products, Inc
Biology Products: